Medtronic plc Stock

Equities

MDT

IE00BTN1Y115

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-04-15 pm EDT 5-day change 1st Jan Change
80.23 USD +0.12% Intraday chart for Medtronic plc -3.23% -2.61%
Sales 2024 * 32.24B Sales 2025 * 33.58B Capitalization 106B
Net income 2024 * 4.55B Net income 2025 * 5.24B EV / Sales 2024 * 3.99 x
Net Debt 2024 * 22.3B Net Debt 2025 * 21.07B EV / Sales 2025 * 3.8 x
P/E ratio 2024 *
22.9 x
P/E ratio 2025 *
19.8 x
Employees 95,000
Yield 2024 *
3.44%
Yield 2025 *
3.61%
Free-Float 99.82%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Medtronic plc

1 day+1.46%
1 week-5.24%
Current month-8.06%
1 month-5.05%
3 months-8.34%
6 months+11.35%
Current year-2.73%
More quotes
1 week
79.56
Extreme 79.56
83.83
1 month
79.56
Extreme 79.56
87.73
Current year
79.56
Extreme 79.56
89.18
1 year
68.84
Extreme 68.84
92.02
3 years
68.84
Extreme 68.84
135.89
5 years
68.84
Extreme 68.84
135.89
10 years
55.54
Extreme 55.54
135.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 15-01-25
Director of Finance/CFO 58 16-05-31
Chief Operating Officer 60 21-03-31
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 70 06-12-31
Director/Board Member 68 14-12-31
More insiders
Date Price Change Volume
24-04-15 80.23 +0.12% 7,500,202
24-04-12 80.13 -2.48% 6,562,831
24-04-11 82.17 -0.19% 5,241,326
24-04-10 82.33 -1.75% 6,509,396
24-04-09 83.8 +1.07% 5,681,094

Delayed Quote Nyse, April 12, 2024 at 04:00 pm EDT

More quotes
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
80.13 USD
Average target price
94.86 USD
Spread / Average Target
+18.38%
Consensus